The efficacy of current anti-cancer gene therapies is limited by the inability of gene vectors to penetrate the poorly vascularized, hypoxic regions of tumors, leaving these sites untreated. We describe a new approach for targeting gene therapy to these sites, which employs an attenuated strain of the non-pathogenic bacterium, Salmonella typhimurium, carrying an exogenous (that is, reporter or therapeutic) gene under the regulation of a new, highly hypoxia-inducible promoter (FF+20 *). This bacterial vector was seen to rapidly migrate into, and thrive in, hypoxic areas of both mammary tumor spheroids grown in vitro and orthotopic mammary tumors after systemic injection. Using the reporter gene construct, FF+20 *-lacZ, we show that bacterial expression of high levels of b-galactosidase occurred only in hypoxic/necrotic sites of spheroids and tumors. We then replaced the reporter gene with one encoding a novel cytotoxic protein (HlyE) and showed that this was also expressed by bacteria only in hypoxic regions of murine mammary tumors. This resulted in a marked increase in tumor necrosis and reduced tumor growth. Our system represents a promising new strategy for delivering gene therapy to poorly vascularized regions of tumors and shows, for the first time, the efficacy of HlyE as an anti-tumor agent.
Introduction
The long-term efficacy of conventional anti-cancer agents like cytotoxic drugs or genes remains unsatisfactory, with poor survival rates for patients with most forms of cancer. This is, in part, due to their inadequate delivery to the tumor site and/or poor selectivity for tumor cells. The problem is compounded by the fact that newly formed blood vessels in tumors are highly irregular and poorly organized, leading to the formation of multiple regions of hypoxia (o1% oxygen) or anoxia (0% oxygen).
1,2 Systemic therapeutic agents do not penetrate far beyond the tumor vasculature, and therefore fail to access the poorly vascularized, hypoxic areas. Moreover, hypoxic tumor cells are often non-proliferating and are therefore relatively refractory to many forms of chemotherapy. Although alternative strategies to target drugs or therapeutic genes are being developed, their systemic delivery remains severely limited due to inadequate vascular supply. This prompted the search for cellular vectors, which, after systemic administration, actively migrate into hypoxic regions of tumors.
Tumors provide a haven for many types of bacteria, including Clostridia, Bifidobacterium, and the gramnegative, facultative anaerobe, Salmonella typhimurium. 3 This is partly due to the ability of the bacteria to thrive in the challenging conditions present in hypoxic/ necrotic regions of tumors, where they also evade immune clearance. 3 Non-pathogenic, attenuated strains of S. typhimurium accumulate in tumors when administered systemically to tumor-bearing mice. However, such bacterial vectors also infect some healthy tissues, [4] [5] [6] [7] therefore an additional level of targeting is required to ensure that therapeutic gene expression is restricted to the tumor site. One option is to place the therapeutic gene under the control of a promoter that is responsive to a tumor-specific condition such as hypoxia.
As a facultative anaerobe, Salmonella expresses a transcription factor, the Fumarate and Nitrate Reduction regulator, FNR, which responds to oxygen availability and activates gene expression under anaerobic conditions. 8 Oxygen availability is sensed by FNR through the assembly-disassembly of oxygen-labile [4Fe-4S] 2+ clusters. Hypoxia/anoxia allows iron-sulphur cluster acquisition, FNR dimerization and enhanced binding to specific DNA sequences (TTGATnnnnATCAA) in target promoters. On binding, FNR recruits RNA polymerase allowing transcription of the downstream gene. When oxygen levels increase the iron-sulphur clusters are disassembled and FNR is released from the target DNA and gene expression ceases.
We hypothesized that an FNR-responsive promoter could be used to restrict gene expression in bacterial vectors to hypoxic regions of tumors. Therefore we designed a form of the FNR-dependent promoter that is highly responsive to severe hypoxia, and used it to activate expression of a reporter (lacZ) or novel therapeutic gene (one encoding the bacterial cytolysin, HlyE) [12] [13] [14] in an attenuated strain of S. typhimurium in hypoxic regions of both mammary tumor spheroids in vitro and mammary tumors in vivo. In the case of tumor targeting of the HlyE gene, the targeted expression of such a cytotoxic agent in hypoxic sites of tumors causes widespread tumor cell death and significantly reduced tumor growth.
Results
Design of a hypoxia-responsive reporter gene fusion in S. typhimurium
To restrict reporter or transgene expression to hypoxic regions of tumors, it was important to generate a promoter with negligible activity in normoxic conditions and high activity under hypoxic/anoxic conditions. To achieve this we began with an oxygen-responsive, semisynthetic bacterial promoter, FF+20, which is regulated in S. typhimurium by the hypoxia-responsive transcription factor, FNR, binding at a site located at À61.5 relative to the transcription start site. We maximized the dependence of FF+20 on FNR by mutating the À10 promoter element, reasoning that a weaker À10 hexamer should make recognition of the FF+20 promoter by RNA polymerase more dependent on FNR.
The S. typhimurium strain JRG4401 was used as the host for plasmids containing derivatives of FF+20 fused to the lacZ gene (encoding b-galactosidase). Expression of lacZ by the unaltered FF+20 promoter was enhanced nine-fold in S. typhimurium in hypoxic conditions compared with normoxic conditions (Figure 1a ). However, a mutated derivative (FF+20*) with a point mutation in the À10 element (CATAAT-CATCAT) exhibited a 625-fold induction of lacZ expression in hypoxic conditions (Figure 1a) . Importantly, FF+20* driven lacZ expression in normoxic conditions was negligible ( Figure 1a) . Moreover, we showed that the FF+20* promoter retained 84 and 77% activity in severe hypoxic conditions (0.1 and 0.5% O 2 , respectively; Figure 1b ), which is equivalent to pathological levels of hypoxia in vivo [15] [16] [17] [18] and importantly, that FF+20* driven lacZ expression returned to a minimal level (4% activity) in mild hypoxic or normoxic conditions (X5% O 2 ; Figure  1b ). Thus we have designed a promoter, FF+20*, with the characteristics necessary to restrict transgene expression to severely hypoxic tissues and ensure negligible expression in extra-tumoral (that is, normoxic) tissues.
Expression of lacZ in murine mammary tumor cells infected with JRG4401(FF+20*-lacZ) in vitro After co-culture of 4T1 cell monolayers with JRG4401(FF+20*-lacZ) followed by removal of extracellular bacteria, positive X-gal staining was detected after exposure of infected cell monolayers to hypoxia, but not to normoxia, for 6 h (Figure 2a ). This resulted in a 47-fold increase in the numbers of lacZ-positive bacteria under hypoxic conditions, indicating that the FF+20* is an effective oxygen-responsive promoter (Figure 2b ). Uninfected monolayers of 4T1 cells grown in hypoxic conditions were also X-gal stained to visualize any increase in endogenous b-galactosidase caused by lower oxygen concentration, dying cells and/or acidic conditions. No changes in endogenous b-galactosidase were observed (data not shown).
4T1 spheroids were co-cultured with JRG4401(FF+20*-lacZ) processed and immunostained for pimonidazole, S. typhimurium or b-galactosidase. This confirmed that cells in the inner, peri-necrotic rim of 4T1 spheroids were hypoxic, as indicated by positive immunostaining for pimonidazole adducts (Figure 3a) . Furthermore, although bacteria infiltrated throughout the viable rim of spheroids, occupying both intracellular and extracellular niches (Figure 3c ), the expression of b-galactosidase was confined to the inner hypoxic/anoxic layers of the spheroids (Figure 3e ). The in vitro studies indicated that the hypoxia-responsive bacterial FF+20* promoter was able to drive reporter gene expression in hypoxic regions of 4T1 spheroids. Before testing the ability of the FF+20* promoter to restrict gene expression to hypoxic regions of tumors in vivo, the Salmonella strain was further attenuated by disruption of purI gene, resulting in the strain JRG5356(FF+20*-lacZ). Mutating the purI gene not only reduces the pathogenicity of Salmonella, 6, 19 but helps to target these bacteria to hypoxic areas, as purI mutation imposes a requirement for adenine (found at the highest concentrations in the necrotic, hypoxic areas of tumors due to the rapid turnover of tumor cells) needed for bacterial survival. The S. typhimurium strain JRG4401(FF+20*-lacZ), which was used throughout the in vitro studies described here, carried lesions in the waaN and aroA genes. Salmonella waaN mutants have decreased ability to induce the release of TNFa and thus are less likely to induce TNFa-mediated toxic shock. 1, 20 The aroA mutation imposes a requirement for aromatic amino acids needed for survival, making it likely that the bacteria will preferentially proliferate in necrotic and peri-necrotic (that is, hypoxic) regions. Thus, the new strain JRG5356(FF+20*-lacZ), carrying mutations in the aroA, waaN and purI genes, was more likely to be nonpathogenic in tumor-bearing mice, whereas retaining the ability to accumulate in the nutrient-rich tumor environment. A pilot study, in which six female BALB/c tumorbearing mice received a single intravenous injection of 106 cfu (colony-forming units) of JRG5356, showed that the bacteria was well tolerated with no deaths or other signs of morbidity after 14 days.
Immunohistochemical analyses of 4T1 tumors ten days post bacterial inoculation showed a high level of infiltration by S. typhimurium throughout the tumors (brown stain), with the most intense staining of the bacterial marker in hypoxic (red stain) areas (Figures 3d  and b , respectively). Expression of b-galactosidase (brown stain) was restricted to hypoxic areas and was absent in well-oxygenated regions of tumors (Figure 3f ). Although bacteria were present in the liver and spleen of these mice, no pimonidazole or b-galactosidase was detected (data not shown). b-galactosidase was also not detected in the mice injected with Salmonella carrying a promoterless lacZ reporter (data not shown). Thus, systemic administration of JRG5356(FF+20*-lacZ) to tumor-bearing mice resulted in preferential accumulation of bacteria in the tumors and restricted reporter gene expression to hypoxic/anoxic regions.
HlyE cytotoxicity
The pore-forming cytolysin, HlyE, is produced by several bacteria such as E. coli, 12 Shigella flexneri 2a 21 and Salmonella enterica serovars typhi and paratyphi A 22 to attack mammalian cells. 4, 23, 24 Thus, if appropriately targeted, HlyE could be used to lyse tumor cells. When exposed to HlyE protein (X0.5 mg ml À1 ), 4T1 tumor cells showed a marked increase in lactate dehydrogenase (LDH) release (Figure 4a ), indicative of damage to the plasma membrane and therefore cytotoxicity.
Having shown the potential of HlyE to lyse tumor cells, new plasmids were constructed in which hlyE (FF+20*-hlyE) or a truncated portion of the hlyE gene (FF+20*-thlyE; encoding an inactive protein) were placed downstream of the FF+20* promoter. In addition, the hok/ sok genes were engineered into the new plasmids to ensure retention of the plasmid within the bacteria when the strain was injected into the mouse model. 25 The FF+20*-thlyE construct was designed to provide an ideal control for subsequent experiments because it produces an inactive truncated HlyE (tHlyE) protein, but places a near identical genetic and biochemical load on Salmonella as the FF+20*-hlyE construct.
Immunoblotting using anti-HlyE serum showed that HlyE was only detected when JRG5356(FF+20*-hlyE) were grown in hypoxic conditions (Figure 4b ). Furthermore, to show that the HlyE expressed and released by JRG5356(FF+20*-hlyE) was cytotoxic, we co-cultured 4T1 cells with either JRG5356(FF+20*-hlyE) or JRG5356(FF+20*-thlyE) in normoxic and hypoxic conditions in vitro, and measured LDH release. All the bacterial strains caused similar amounts of LDH release under normoxic conditions, and as the number of (a) Monolayers of 4T1 cells were incubated with increasing concentrations (0, 0.5 and 5 mg ml À1 ) of purified HlyE protein or a control protein (ovalbumin) for 22 h in normoxia or hypoxia and cell death assessed. *Po0.0001 with respect to control group at the same concentration. (b) S. typhimurium expressing FF+20*-hlyE was cultured for 22 h in normoxic or hypoxic conditions, then the media was removed, concentrated and probed on an immunoblot with anti-HlyE sera (first panel). Purified HlyE was used as a positive control. The second panel is the Coomassie stained gel to show equal loading of FF+20*-hlyE grown under normoxic and hypoxic conditions. (c) Monolayers of 4T1 cells were co-cultured with increasing concentrations (10 1 -10 9 ) of S. typhimurium JRG5356 alone (first pair at each concentration) or S. typhimurium JRG5356 expressing either FF+20*-thlyE (the truncated hlyE, which is an inactive protein; second pair at each concentration) or FF+20*-hlyE (third pair at each concentration) under normoxic and hypoxic conditions for 22 h. Cell death was assessed through LDH release. All data are shown as mean±s.e.m. and represent data pooled from three independent experiments. *Po0.002 with respect to normoxia and the hypoxic FF+20*-thlyE group at the same concentration.
Bacterial targeting to tumors RM Ryan et al bacteria in the inoculum increased the amount of LDH released after 22 h co-incubation increased (Figure 4c ). Thus, under these conditions Salmonella alone in coculture damaged 4T1 cells. Similar amounts of LDH release were obtained after co-culture of 4T1 with Salmonella alone or Salmonella expressing the inactive tHlyE under anoxic conditions (Figure 4c) . However, at all bacterial cell densities used, JRG5356(FF+20*-hlyE) caused significantly increased cytotoxicity (Figure 4c) . The enhanced cytotoxicity of JRG5356(FF+20*-hlyE) clearly showed that active HlyE was exported from the bacteria.
Biodistribution of JRG5356(FF+20 *-hlyE/thlyE) in murine tissues
Ten days after intravenous administration of 10 6 cfu of either JRG5356(FF+20*-hlyE) or JRG5356(FF+20*-thlyE) to mice bearing 4T1 tumors, bacterial cfu counts indicated up to 10 9 cfu per gram tumor, whereas approximately only 10 4 cfu per gram tumor were found in the liver, equivalent to a tumor/liver ratio of approximately 10 000:1, showing preferential accumulation of JRG5356 in tumors (Figure 5a ). Importantly, bacteria were not detectable in the bone marrow, known to contain areas of severe hypoxia.
Bacterial delivery of FF+20 *-hlyE to hypoxic areas of 4T1 tumors in vivo
Having established that the expression of a reporter gene (lacZ) under the control of FF+20* is confined to the hypoxic and necrotic regions of 4T1 tumors in vivo, and that the biodistribution of JRG5356(FF+20-hlyE) was appropriate, we tested the anti-tumor effects of hypoxia-targeted expression of hlyE. Tumor growth was significantly retarded in mice treated with JRG5356(FF+20*-hlyE) expressing active HlyE, compared with mice treated with JRG5356(FF+20*-thlyE) expressing an inactive, truncated HlyE (Figure 5b ). Mean tumor volumes were decreased by 43% within 10 days for mice treated with JRG5356(FF+20*-hlyE), with a significant 
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RM Ryan et al difference observed within 6 days of treatment (*Po0.01). Furthermore, the extent of necrosis in tumors from the JRG5356(FF+20-hlyE) treated mice was significantly (Po0.05) greater than for mice treated with JRG5356(FF+20-thlyE) (Figure 5c ), consistent with the cytotoxic effect of HlyE on 4T1 cells in vitro. Finally, JRG5356(FF+20-hlyE) and JRG5356(FF+20-thlyE) were found to be present in the lungs ( Figure 5a) ; however, there was no effect on the formation of pulmonary metastases in tumor-bearing mice (although a longer treatment period may be required; data not shown).
Discussion
Many cancer trials using an array of gene therapy protocols have highlighted the need for improved delivery vehicles to effectively target therapeutic genes to tumors. 26, 27 In the absence of these, many have now resorted to direct intratumoral injection of the gene vector. However, this has the major limitation of being unable to deliver therapeutic genes to inaccessible primary tumors or metastatic sites.
Other groups have shown that attenuated strains of S. typhimurium preferentially accumulate in tumors in vivo, partly because these bacteria require metabolites for survival, which are released in hypoxic/necrotic regions. 3 Such regions also represent an immunological sanctuary in which bacterial clearance mechanisms are reduced. 28 Use of attenuated Salmonella as a delivery vector is advantageous as they can be delivered systemically, can infiltrate a range of tumor types 4 and are safe for human administration. 29 Furthermore, S. typhimurium accumulates in tumors as small as 50 mm 3, 4 possibly because they contain relatively large regions of hypoxia and necrosis, 30, 31 therefore it is possible to use them to treat small metastatic tumors in vivo.
Even though this attenuated strain of S. typhimurium has an impressive tumor/liver ratio of 10 000:1, they were present in some normal tissues when injected systemically, which could result in extra-tumoral gene expression. We overcame this issue by coupling S. typhimurium with a bacterial transcriptional targeting mechanism to restrict the expression of the therapeutic gene to hypoxic areas within tumors and minimize expression in normal, normoxic tissues.
Attempts have been made to use mammalian, hypoxia-responsive promoter elements to target gene therapy to hypoxic regions of tumors. 32, 33 However, delivery to poorly vascularized regions after systemic application of viral or cellular vectors is yet to be shown. Other studies have used the pepT gene promoter to target hypoxiainducible gene expression in bacteria to tumors. 34 The promoter described here has a weaker À10 element than that of the pepT promoter and has the FNR-binding site located further upstream of the transcript start site (À61 bp upstream compared with À41 bp for the modified pepT promoter). These features were designed to make the FF+20* promoter more FNR-dependent (due to its weaker À10 element) and to reduce the number of protein/protein contacts used to recruit RNA polymerase to the promoter (as the FNR-binding site was further upstream of the transcription start site). The effect of these features is to lower the activity of the promoter under normoxic conditions and to impose a requirement for high concentrations of active, intracellular FNR compared with the unaltered FF+20 promoter ( Figure  1 ), resulting in a promoter that is at least as effective as the modified pepT promoter.
To test the therapeutic potential of our Salmonellabased gene targeting system, we combined it with a novel therapeutic agent-the bacterial cytolysin, HlyE. HlyE is a pore-forming protein capable of lysing a range of mammalian cell types, 4, 35 including 4T1 cells (Figures  4 and 5) . The marked increase in tumor necrosis and reduction in tumor volume (43%) achieved after intravenous administration of JRG5356(FF+20-hlyE) shows the potential for using our hypoxia-targeted Salmonella vector to deliver cytotoxins to hypoxic regions of tumors, and shows the profound cytotoxicity of HlyE by inhibition of tumor growth and viability and induction of necrosis.
The outcome of hypoxia-targeted HlyE expression is likely to be dependent on the extent of the hypoxic fraction of tumors, and entry, survival and replication of S. typhimurium in these regions. 28 Thus, administration of chemotherapy agents or vasculature-damaging compounds like combretastatin, 36 which increase tumor hypoxia is likely to amplify the efficacy of our Salmonella-based gene delivery system.
In summary, we have developed a system with two independent levels of tumor targeting: (i) an attenuated strain of S. typhimurium as a delivery vector that preferentially accumulates within hypoxic areas of solid tumors, and (ii) a highly hypoxia-inducible bacterial promoter to restrict therapeutic gene expression to these tumor regions. Moreover, we have shown that this system effectively delivers a novel bacterial cytolysin (HlyE) that is expressed from a plasmid maintained by a plasmid addiction system, thereby avoiding the use of antibiotics to maintain therapeutic gene expression, to hypoxic sites of murine tumors, resulting in widespread tumor destruction and reduced tumor growth. Thus, this new system represents a promising strategy for delivering gene therapy to largely inaccessible areas of solid tumors.
Materials and methods

Bacterial strains and plasmids
Relevant characteristics of the bacterial strains and plasmids used are given in Table 1 
PCR-based site-directed mutagenesis
Specific point mutations were introduced into a semisynthetic lacZ reporter fusion FF+20pmelR in which the class I FNR-binding site is located 61.5 bp upstream of the transcription start site. This was carried out by overlap extension PCR, essentially as described by Hutchinson, 39 using appropriate mutagenic and flanking primers. The authenticity of the mutations was confirmed by automated DNA sequencing after ligation into the pRW50-based plasmid in which the mutated FF+20* was fused to the lacZ gene (encoding b-galactosidase).
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This was then transformed into JRG4401 to give JRG4401(FF+20*-lacZ) and was used along side the unmutated sequence JRG4401(FF+20-lacZ) throughout the in vitro studies described here.
Initial experiments used the reporter plasmid, FF+20*-lacZ, which is resistant to tetracycline and which therefore needs to be included in all in vitro and in vivo experiments. To increase plasmid segregational stability in bacterial cells, we developed a pRW50-based plasmid in which the therapeutic transgene was fused to a postsegregational killing loci (hok + /sok + pnd + ). 25 This sequence was amplified from pDD1025 and was included to ensure that tetracycline did not need to be added to the in vivo experiments. The therapeutic transgene, hlyE, was amplified from pGS1111 fused to the killer loci and ligated into FF+20* to create FF+20*-hlyE. We also developed an identical construct in which only the amino-terminal region of the hlyE gene, which has been shown to be sufficient for export, but is not cytotoxic, 40 was included to create FF+20*-thlyE. The authenticity of the altered plasmids was confirmed by automated DNA sequencing.
To administer to mice in the later in vivo studies, JRG4401 was further attenuated to reduce pathogenicity, by disrupting the purI gene with a chloramphenicol acetyltransferase (cat)-resistant cassette by linear transformation, as described earlier. 41 The purI-cat lesion was confirmed by PCR using appropriate primers and the strain was designated JRG5356. This strain was then transformed with either FF+20*-lacZ, FF+20*-hlyE or FF+20*-thlyE to create either JRG5356(FF+20*-lacZ), JRG5356(FF+20*-hlyE) or JRG5356(FF+20*-thlyE).
Cell lines and culture media
Murine mammary 4T1 adenocarcinoma cells (originally derived from a spontaneously arising mammary tumor from a BALB/cfC 3 H mouse) 42 were maintained and monitored by light microscopy (Leica Microscopy UK Ltd, Milton Keynes, UK.) in monolayer cultures in RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum and were kept in an atmosphere of 5% CO 2 in air at 37 1C. For administration to mice, tumor cells were harvested from subconfluent cultures, with 0.25% (w/v) trypsin-0.02% (w/v) EDTA. Trypsin was neutralized with medium containing 10% fetal bovine serum, washed three times in Ca 2+ /Mg 2+ -free phosphate buffered saline (PBS) and resuspended in PBS at 5 Â 10 5 ml
À1
for injection. Only single cell suspensions of 495% viability, as determined using the trypan blue exclusion assay, were used for injections.
In vitro experiments Reporter gene (lacZ) assays. Cultures of JRG4401
(FF+20*-lacZ) were grown to mid-exponential phase (OD 600 of 0.3-0.6) in LB broth containing tetracycline (35 mg ml
) at 37 1C. Normoxic (20.9% O 2 ) cultures were grown in shaken (250 rpm) conical flasks (250 ml) containing 5 ml of medium. Anoxic cultures were grown in 5 ml volumes in sealed bottles. Hypoxic (0.5% O 2 ) and other oxygen concentration (0.1, 1, 2.5 and 5%) cultures were grown in 5 ml volumes using Heto multigas incubators with 5% CO 2 and the balance being made up with nitrogen. b-galactosidase activities were determined as described by Miller. 43 Co-culture of tumor cells with S. typhimurium 4T1 cells were seeded into 24-well lumox plates (Vivascience, Gloucestershire, UK) and grown to 70% confluence under normoxic conditions. Monolayers were then co-cultured with 10 6 cfu ml À1 of JRG4401(FF+20*-lacZ) in RPMI-1640 supplemented with 35 mg ml À1 tetracycline and allowed to infect the monolayers for 6 h under both normoxic (20.9% oxygen) and hypoxic (0.5% oxygen) conditions, as described earlier. 44 All extracellular bacteria were killed by incubation with gentamicin (500 mg ml À1 for 20 min). This was confirmed with cfu counts of the media. After removing dead bacteria by extensive washing with PBS, the monolayers were then either assayed for b-galactosidase using the above assays or lacZ expression was visualized using Xgal staining.
Infected monolayers were fixed in 0.25% (v/v) gluteraldehyde for 20 min and stained (1 mg ml À1 X-gal in dimethylformamide, 4 mM potassium ferricyanide, 4 mM potassium ferrocyanide and 2 mM magnesium chloride) at 37 1C for 8-16 h. The reaction was stopped by washing in 3% (v/v) dimethylsulfoxide followed by PBS.
Co-culture of spheroids with S. typhimurium
Tumor spheroids were used as an in vitro model of tumor hypoxia. These are spherical 3-D tumor masses grown in culture from a non-adherent culture of 4T1 tumor cells and are known to consist of an inner necrotic core surrounded by an outer, multicellular, viable rim of tumor cells, the inner part of which is severely hypoxic. Bacterial targeting to tumors RM Ryan et al 4T1 spheroids were prepared using the protocol we have described earlier for spheroids made from the human breast cancer cell line, T47D. 46 After 10-14 days of growth in non-adherent, overlay cultures, spheroids were incubated with 10 6 cfu of JRG4401(FF+20*-lacZ) in RPMI-1640 supplemented with 35 mg ml À1 tetracycline. After 6-12 h, excess bacteria were removed and all extracellular bacteria were killed by incubation with gentamicin, as described above. The media was then replaced with a solution of 170 mM pimonidazole, a hypoxic cell marker (Hypoxyprobe-1; Chemicon International, Billerica, MA, USA.) in RPMI-1640 for further 2 h, to label hypoxic cells in the spheroids. These were visualized by immunohistochemistry of spheroid sections (see below). The spheroids were then washed in PBS, fixed in formalin, wax embedded and sectioned by standard histological techniques.
Production and cytotoxicity of HlyE
The HlyE protein was isolated and quantified from a GST-HlyE-overproducing strain (pGS1111) as described earlier. 35 Cytotoxicity of HlyE was determined using an in vitro lactic dehydrogenase-based, toxicology kit (Sigma), according to the manufacturers' instructions. Briefly, 4T1 cells were seeded at a density of 2 Â 10 4 for 3 h in serum free media in 96-well plates. Purified HlyE protein was added to the cells at concentrations ranging from 0.1 to 5 mg ml À1 in serum free media (100 ml) and incubated under normoxic and hypoxic conditions for 22 h. Cells were pelleted and the media was assayed for extracellular LDH activity. The plate was read at 490 nm with a Denley plate reader. Ovalbumin was used as a protein control. Relative cytotoxicity was calculated as 100 Â (experimental release/total release) in which total release is the amount of LDH activity in 4T1 cell lysates after treating with lysis buffer provided with the kit.
Export of HlyE under hypoxic conditions. To confirm that JRG5356(FF+20*-hlyE) exports detectable HlyE under hypoxic conditions, JRG5356(FF+20*-hlyE) was grown in LB broth supplemented with chloramphenicol and tetracycline at 10 and 35 mg ml À1 , respectively, under both normoxic and hypoxic conditions. The concentration of extracellular protein in the media was estimated with the BioRad protein reagent and equivalent concentrations were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. 47 The protein was transferred using standard western blotting techniques and probed with polyclonal anti-HlyE serum (1:10 000). This was raised in rabbits, in house against the full-length HlyE protein. This was followed by horseradish peroxidaseconjugated goat anti-rabbit IgG (Dako). Immune complexes were visualized by chemiluminescence using the Amersham ECL Plus detection system. Export and cytotoxicity of HlyE under hypoxic conditions. To confirm that JRG5356(FF+20*-hlyE) exports a cytotoxic form of HlyE under hypoxic conditions only, we co-cultured 4T1 cells, which were seeded at a density of 2 Â 10 4 for 3 h in serum free media in 96-well plates with increasing concentrations (10 1 - 10 9 ) of either JRG5356, JRG5356(FF+20*-hlyE) or JRG5356(FF+20*-thlyE) under normoxic and hypoxic conditions. The LDH content of the media was measured after 22 h according to the manufacturer's instructions (as described above). Relative cytotoxicity was calculated as described above.
In vivo experiments Experimental design for reporter gene analysis. Female 10-week old BALB/c mice (Charles River Institute, Margate, UK) were acclimatized for 1 week, caged in groups of five or less at ambient temperature of 21-22 1C and 50% humidity with a 12 h light-dark cycle. Animals were housed in a licensed biomedical facility (RCSI Department of Surgery) and all procedures were reviewed by the RCSI Ethics committee and carried out under animal license guidelines of the Department of Health, Ireland and in accordance with the UK Co-ordinating Committee on Cancer Research Guidelines for the welfare of animals in experimental neoplasia. Animals had ad libitum access to water and animal chow (WM Connolly and Sons Ltd., Kilkenny, Ireland). After anesthesia (induced and maintained with inhalational Halothane), 5 Â 10 4 (100 ml) 4T1 cells were injected into the mammary fat pad adjacent to the left forefoot through a surgical incision. The diameter of primary tumors was measured on alternate days after injection of tumor cells. When mean tumor diameter was 10 ± 0.5 mm (day 9 after implantation) mice were randomized into three groups (n ¼ 8/group). Two groups received 10 6 cfu in saline of either JRG5356(FF+20*-lacZ) or JRG5356(promoterless lacZ) through lateral tail vein injection. All mice received tetracycline (1 mg ml À1 ) in the drinking water. Tumors were measured individually every other day using callipers and volume was determined using the formula (l Â b 2 /2, where l is length and b is breath). Ten days after infection, all mice received an intraperitoneal injection of 60 mg kg À1 solution of pimonidazole in saline 90 min before euthanasia. 48 Primary tumors and other organs were excised aseptically either snap frozen or fixed in formalin, wax embedded and sectioned by standard histological techniques.
Experimental design for therapeutic gene analysis. For the second round of experiments, mice were treated in the same way as above, but each group (n ¼ 10/group) received 10 6 cfu of either JRG5356(FF+20*-hlyE) or JRG5356(FF+20*-thlyE) in saline through lateral tail vein injection. Ten days after infection, all mice received an intraperitoneal injection of 60 mg kg À1 solution of pimonidazole in saline 90 min before euthanasia, 48 and primary tumors and other organs were removed aseptically. Part of the organ was analyzed for bacterial biodistribution and the remaining tissue was either snap frozen or fixed in formalin or zinc, wax embedded and sectioned by standard histological techniques.
Biodistribution of JRG5356(FF+20*-hlyE) and JRG5356(FF+20*-thlyE) in tissues and analysis of lung metastases. Organs (n ¼ 5) were weighed and homogenized aseptically in 3 ml of ice-cold, sterile PBS. The homogenate was then serially diluted and plated onto LB agar supplemented with chloramphenicol at 35 mg ml
À1
, to select for salmonellae in the presence of any contaminating bacteria. Petri dishes were incubated at 37 1C for 16 h. The cfu per gram tissue was determined by counting colonies and dividing them by the weight of the specific organ. Harvested lungs from mice per group (n ¼ 5) were fixed in Bouins solution for 24 h and the number and size of lung lesions determined using a dissecting microscope.
Immunohistochemistry. Three sequential sections (5 mm) of paraffin wax embedded spheroids or mouse tissues were immunostained for pimonidazole to identify hypoxic regions (using a polyclonal antibody kindly supplied by Dr James Raleigh), S. typhimurium (using a polyclonal antibody raised against Salmonella-specific 'O/H' antigens, from Biogenesis, Poole, UK.) and b-galactosidase (using a polyclonal anti-b-galactosidase, from Abcam, Cambridge, UK).
Immunostaining for hypoxic cells was carried out essentially as described recently, 49 using the primary antibody, anti-pimonidazole at a dilution of 1:8000. The immunostaining protocol for analysis of S. typhimurium and b-galactosidase was as follows: after dewaxing and rehydration, endogenous peroxidase in cells/sections was blocked using 3% H 2 O 2 in methanol for 20 min followed by microwave antigen retrieval (800 W in 0.1 mol l À1 tri-sodium citrate, pH 7.4 for 8 min). Sections were then washed in PBS and incubated in 1% v/v normal goat serum for 30 min at room temperature (Vector Laboratories, Peterborough, UK), then for 30 min at room temperature in the following dilutions of primary antibodies: anti-O/H antigens, 1:200 and antib-gal, 1:5000. A standard three stage immunoperoxidase technique was then used (Vector Laboratories Elite ABC kit) together with either the brown chromagen, 3,3 0 -diaminobenzidine (for S. typhimurium and b-galactosidase), and the red chroagen, Vector Red (for pimonidazole to identify hypoxic cells). Finally, sections were counterstained with haematoxylin, dehydrated, cleared and mounted using aquamount.
Assessment of tumor necrosis. Serial (5 mm) sections were cut of paraffin wax embedded 4T1 tumors from mice injected with either JRG5356(FF+20*-thlyE) or JRG5356(FF+20*-hlyE). Sections were then dewaxed, rehydrated and stained in Ehrlich's haematoxylin and eosin according to standard histological methods. The sections were then photographed unblended by light microscopy (Olympus) and AnalySIS software was used to measure both the total cross-sectional area of each tumor and the area of necrosis present within each tumor. Areas of necrosis were characterized by the disruption of the plasma, organelle breakdown and cell lysis. The percentage of necrosis in each tumor section was then calculated.
Statistical analysis. Data are expressed as means ± standard errors (s.e.m). Differences between treatment groups were determined using a two-tailed student's t-test and data are taken as significant where Po0.05.
